Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 10,000 shares at $1.87 ($19K) on 2015-05-04, disclosed to the SEC on 2015-05-04.
Scheduled sale ($19k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.85 | 3,700 | $7K | 36.9% |
| 2 | $1.86 | 2,700 | $5K | 27.0% |
| 3 | $1.86 | 3,000 | $6K | 30.1% |
| 4 | $1.87 | 600 | $1K | 6.0% |
| Total | $1.86 avg | 10,000 | $19K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |